{"id":"pet-mpi","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":null,"effect":"Stress-induced symptoms (chest discomfort, dyspnea, arrhythmia)"}]},"_chembl":{"chemblId":"CHEMBL233133","moleculeType":"Protein","molecularWeight":"1019.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PET MPI (Positron Emission Tomography Myocardial Perfusion Imaging) employs a positron-emitting radiopharmaceutical to assess coronary artery perfusion and myocardial viability. The tracer accumulates in areas of adequate blood flow, allowing clinicians to identify regions of ischemia or infarction. This diagnostic imaging approach helps stratify cardiac risk and guide treatment decisions in patients with suspected or known coronary artery disease.","oneSentence":"PET MPI is a myocardial perfusion imaging agent that uses a radioactive tracer to visualize blood flow to the heart muscle during stress and rest conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:40.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myocardial perfusion imaging for detection and assessment of coronary artery disease"},{"name":"Evaluation of myocardial viability in patients with prior myocardial infarction"}]},"trialDetails":[{"nctId":"NCT03275584","phase":"PHASE4","title":"Safety of PET MPI Using the CRCHUM N-13 Ammonia","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2018-01-30","conditions":"N-13 Ammonia Safety","enrollment":20000},{"nctId":"NCT07439133","phase":"PHASE3","title":"Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)","status":"RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2025-11-14","conditions":"Coronary Artery Disease(CAD)","enrollment":395},{"nctId":"NCT06814587","phase":"","title":"Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-07-01","conditions":"Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)","enrollment":15},{"nctId":"NCT05134012","phase":"PHASE3","title":"RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)","status":"RECRUITING","sponsor":"MedTrace Pharma A/S","startDate":"2022-05-08","conditions":"Coronary Artery Disease","enrollment":215},{"nctId":"NCT07187895","phase":"PHASE2","title":"Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis","status":"TERMINATED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2024-12-19","conditions":"Myocardial Perfusion Imaging, Diagnostic Certainty, Stable Coronary Artery Disease","enrollment":17},{"nctId":"NCT05625490","phase":"EARLY_PHASE1","title":"Myocardial Perfusion Imaging Galmydar Rest/Stress","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2022-11-11","conditions":"Coronary Artery Disease","enrollment":15},{"nctId":"NCT04316676","phase":"NA","title":"The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-06-16","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT07213219","phase":"NA","title":"PET-MRI of Reward System in Parkinson's Disease With RBD","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2026-01-01","conditions":"Parkinson's Disease (PD)","enrollment":44},{"nctId":"NCT05913999","phase":"","title":"Serial PET MPI in Patients Undergoing Cancer Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Los Angeles","startDate":"2023-06-01","conditions":"Cancer, Chemotherapeutic Toxicity, Coronary Artery Disease","enrollment":60},{"nctId":"NCT06670768","phase":"NA","title":"Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA","status":"RECRUITING","sponsor":"Semmelweis University","startDate":"2024-03-06","conditions":"Coronary Artery Disease, Coronary Computed Tomography Angiography, SPECT","enrollment":50},{"nctId":"NCT06356857","phase":"","title":"Assessing Repeatability and Intra-individual Variability in [O15]H2O-PET Myocardial Perfusion Imaging","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter Hovind","startDate":"2024-04-15","conditions":"Myocardial Blood Flow","enrollment":20},{"nctId":"NCT01334918","phase":"PHASE2","title":"A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-04-26","conditions":"Coronary Artery Disease (CAD)","enrollment":124},{"nctId":"NCT00826280","phase":"PHASE3","title":"Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-03-24","conditions":"Coronary Artery Disease (CAD)","enrollment":347},{"nctId":"NCT06712862","phase":"","title":"A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2025-12-31","conditions":"Ischemic Heart Disease","enrollment":100},{"nctId":"NCT04583787","phase":"NA","title":"xSPECT-based Myocardial Perfusion Scintigraphy: Consistency of Functional Values and Feasibility of Myocardial Uptake Quantitation in Patients With Suspected Coronary Artery Disease","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-12-07","conditions":"Coronary Artery Disease","enrollment":52},{"nctId":"NCT01262625","phase":"NA","title":"Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations","status":"TERMINATED","sponsor":"American College of Radiology","startDate":"2011-05-20","conditions":"Chest Pain, Stable Angina Pectoris, CCS Class I to III, Angina Equivalent","enrollment":1050},{"nctId":"NCT04594941","phase":"PHASE2","title":"A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2022-01-27","conditions":"Coronary Artery Disease (CAD), Ischemic Heart Disease","enrollment":38},{"nctId":"NCT03354273","phase":"PHASE3","title":"An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2018-06-05","conditions":"Coronary Artery Disease (CAD)","enrollment":730},{"nctId":"NCT05885841","phase":"PHASE2","title":"Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD","status":"COMPLETED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-02-15","conditions":"Coronary Artery Disease (CAD)","enrollment":83},{"nctId":"NCT03326167","phase":"","title":"Determination of Coronary Flow Reserve by Dynamic Myocardial Perfusion Scintigraphy","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2017-11-15","conditions":"Coronary Heart Disease","enrollment":15},{"nctId":"NCT01934985","phase":"","title":"Dynamic Cardiac SPECT Imaging","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-03","conditions":"Coronary Artery Disease","enrollment":83},{"nctId":"NCT05195879","phase":"PHASE1","title":"A Study of XTR004 Radiotracer in Healthy Volunteers","status":"COMPLETED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2021-03-23","conditions":"Coronary Artery Disease (CAD), Myocardial Ischemia","enrollment":10},{"nctId":"NCT02043535","phase":"NA","title":"CO2 as a Stress Agent for Perfusion Imaging","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-03-12","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT01347710","phase":"PHASE3","title":"A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.","status":"COMPLETED","sponsor":"Lantheus Medical Imaging","startDate":"2011-06","conditions":"Coronary Artery Disease","enrollment":795},{"nctId":"NCT04596527","phase":"EARLY_PHASE1","title":"18F-FMPP PET MPI in the Detection of Coronary Artery Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-09-15","conditions":"Coronary Disease","enrollment":100},{"nctId":"NCT02720354","phase":"PHASE1","title":"A Phase I Study of a Novel Tracer for Positron Emission Tomography \"PET\" Myocardial Perfusion Imaging \"MPI\"","status":"COMPLETED","sponsor":"Synektik S.A.","startDate":"2016-05","conditions":"Coronary Artery Disease","enrollment":12},{"nctId":"NCT01230905","phase":"PHASE4","title":"Study to Monitor the Effects of Androgen Suppression Treatment on the Heart","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2008-07","conditions":"Prostate Cancer","enrollment":181},{"nctId":"NCT01520025","phase":"PHASE4","title":"Multi-modality Imaging of Ischemia With 18F-FDG PET and CTA","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2011-12","conditions":"Myocardial Ischemia","enrollment":18},{"nctId":"NCT01826773","phase":"PHASE2","title":"CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects","status":"COMPLETED","sponsor":"Fluoropharma, Inc.","startDate":"2013-03","conditions":"Coronary Artery Disease","enrollment":34},{"nctId":"NCT00380198","phase":"PHASE3","title":"A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2006-07","conditions":"Coronary Artery Disease","enrollment":1500},{"nctId":"NCT02863952","phase":"NA","title":"Quantitation of Left Ventricular Ejection Fraction Change From Early Exercise Gated Stress/Rest Tc-99m CZT-SPECT MPI","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2016-09","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT02863939","phase":"NA","title":"Quantitation of Cardiac Output Change by Impedance Cardiography in Subjects Undergoing Exercise Gated Stress/Rest Tc-99m CZT-SPECT MPI","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2016-09","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT01434641","phase":"NA","title":"Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2011-07","conditions":"Coronary Artery Disease","enrollment":102},{"nctId":"NCT01618669","phase":"PHASE3","title":"A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-06","conditions":"Coronary Artery Disease (CAD)","enrollment":1147},{"nctId":"NCT01150578","phase":"","title":"Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography","status":"UNKNOWN","sponsor":"Aiden Abidov","startDate":"2011-12","conditions":"Myocardial Ischemia","enrollment":380},{"nctId":"NCT01368770","phase":"PHASE3","title":"Stress Testing Compared to Coronary Computed Tomographic Angiography in Patients With Suspected Coronary Artery Disease","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2011-07","conditions":"Coronary Artery Disease","enrollment":303},{"nctId":"NCT01221272","phase":"PHASE4","title":"Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-09","conditions":"Myocardial Perfusion Imaging, Myocardial Ischemia","enrollment":81},{"nctId":"NCT00733460","phase":"PHASE1","title":"A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET","status":"COMPLETED","sponsor":"Fluoropharma, Inc.","startDate":"2008-03","conditions":"Coronary Artery Disease","enrollment":12},{"nctId":"NCT01681524","phase":"PHASE3","title":"Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI","status":"WITHDRAWN","sponsor":"Lantheus Medical Imaging","startDate":"2012-11","conditions":"Coronary Artery Disease","enrollment":""},{"nctId":"NCT01085162","phase":"","title":"A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)","status":"WITHDRAWN","sponsor":"Lantheus Medical Imaging","startDate":"2013-03","conditions":"Coronary Artery Disease (CAD)","enrollment":""},{"nctId":"NCT01424774","phase":"","title":"Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2011-09","conditions":"Radiation Exposure","enrollment":155},{"nctId":"NCT01313572","phase":"PHASE3","title":"Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2011-08","conditions":"Coronary Artery Disease","enrollment":197},{"nctId":"NCT00990327","phase":"PHASE3","title":"Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2009-11","conditions":"Coronary Artery Disease","enrollment":863},{"nctId":"NCT01430975","phase":"","title":"Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2011-09","conditions":"Radiation Exposure","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":208,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PET MPI","genericName":"PET MPI","companyName":"GE Healthcare","companyId":"ge-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PET MPI is a myocardial perfusion imaging agent that uses a radioactive tracer to visualize blood flow to the heart muscle during stress and rest conditions. Used for Myocardial perfusion imaging for detection and assessment of coronary artery disease, Evaluation of myocardial viability in patients with prior myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}